Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's Aflibercept Will Become Decision Resources' Proprietary Clinical Gold Standard for the Treatment of Wet Age-Related Macular Degeneration in 2013

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's aflibercept will earn Decision Resources' proprietary clinical gold standard status for wet age-related macular degeneration in 2013 and 2018. A unique future gold standard cannot be identified because neither thought-leader opinion nor available clinical data can show that aflibercept has any advantages or disadvantages relative to Lucentis in terms of efficacy, safety and tolerability or delivery attributes.

The new report entitled Wet Age-Related Macular Degeneration: Future Market Opportunity Hinges on Results of the CATT Trial Comparing Ranibizumab and Bevacizumab also finds that less-frequent dosing is an important unmet need in the treatment of wet age-related macular degeneration according to interviewed experts. Although other product opportunities are also commercially compelling, physician survey results confirm that improvements in dosing frequency represent one of the highest areas of unmet need for this indication.

"Our survey results identified significant unmet need in wet age-related macular degeneration, particularly for emerging agents that can offer improvements over the monthly dosing recommended on Lucentis' U.S. product label. However, future market opportunity will depend on the results of the ongoing CATT trial, which will compare Lucentis to Genentech/Roche/ Chugai's Avastin, and will also compare different dosing regimens of these agents," stated Decision Resources Analyst Martin Quinn.

About the Report

Wet Age-Related Macular Degeneration: Future Market Opportunity Hinges on Results of the CATT Trial Comparing Ranibizumab and Bevacizumab is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED